TYPING METHOD

• US 20190309367A1
• Filed: 06/19/2019
• Published: 10/10/2019
• Est. Priority Date: 12/23/2016
• Status: Active Grant

• Current Assignee: Oxford BioDynamics, PLC
• Original Assignee: Oxford Biodynamics Limited
• Inventors: RAMADASS, Aroul Selvam, HUNTER, Ewan, AKOULITCHEV, Alexandre
• Granted Patent: US 11,535,893 B2
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2521/301 Endonuclease
• CPC Class Codes: C12Q 2521/501 Ligase
• CPC Class Codes: C12Q 2523/101 Crosslinking agents, e.g. psoralen
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development

Abstract

The invention provides a method of determining the epigenetic chromosome interactions which are relevant to an epigenetic test for a neurodegenerative condition.

Claims

1-7. -7:

(canceled)

8. A method of determining the epigenetic chromosome interactions which are relevant to an epigenetic test for a neurodegenerative condition, wherein the test distinguishes between subgroups,

comprising contacting a first set of nucleic acids from the subgroups with a second set of nucleic acids representing an index population of chromosome interactions, and allowing complementary sequences to hybridise,

wherein the nucleic acids in the first and second sets of nucleic acids represent a ligated product comprising sequences from both of the chromosome regions that have come together in the epigenetic chromosome interaction,

and wherein the pattern of hybridisation between the first and second set of nucleic acids allows a determination of which epigenetic chromosome interactions are specific to subgroups in the population,

wherein the subgroups differ in at least one characteristic relevant to the condition, optionally selected from diagnosis, prognosis, likelihood of developing and/or predisposition to the condition.

9. A method according to claim 8 wherein:

the neurodegenerative condition is Alzheimer'"'"'s disease, and/or

the neurodegenerative condition is a dementia or cognitive impairment, and/or

the said characteristic is early pre-symptomatic detection of the condition, and/or

the subgroups are subgroups of the human population, and/or

the first set of nucleic acids is from at least 8 individuals; and

/or

the first set of nucleic acids is from at least 4 individuals from a first subgroup and at least 4 individuals from a second subgroup which is preferably non-overlapping with the first subgroup, and/or

the second set of nucleic acids represents an unselected group of chromosome interactions, and/or

the second set of nucleic acids is bound to an array at defined locations, and/or

the second set of nucleic acids represents chromosome interactions in least 100 different genes or loci, and/or

the second set of nucleic acids comprises at least 1000 different nucleic acids representing at least 1000 different epigenetic chromosome interactions, and/or

the first set of nucleic acids and the second set of nucleic acids comprise nucleic acid sequences of length 10 to 100 nucleotide bases.

14. A method of identifying an agent which is capable of changing the disease state of an individual with a neurodegenerative condition from a first state to a second state comprising determining whether a candidate agent is capable of changing the chromosomal interactions from those corresponding with the first state to chromosomal interactions which correspond to the second state, wherein in the second state the individual lacks a characteristic relevant to the neurodegenerative condition.